Abstract
Despite considerable progress in addressing cardiovascular disease (CVD) over the past 50 years, there remain many gaps in CVD care quality. Multiple missed opportunities have been identified at every step in the prevention and treatment of CVD, such as failure to make risk factor modifications, failure to diagnose CVD, and failure to use proper evidence-based treatments. With the digital transformation of medicine and advances in health information technology, clinical decision support (CDS) tools offer promise to enhance the efficiency and effectiveness of cardiovascular care delivery. Yet, to date, the promise of CDS delivering scalable and sustained value for patient care in clinical practice has not been realized. Here, we review evidence on key emerging questions around the development, implementation, and regulation of CDS with a focus on CVD. We first review evidence on the effectiveness of CDS on patient health and health delivery outcomes related to CVD and features predictive of effectiveness. We then review the barriers encountered during CDS implementation in cardiovascular care with a focus on unintended consequences and strategies to promote successful implementation. Finally, we review the current legal and regulatory environment of CDS with specific examples for CVD.
Competing Interest Statement
In the past three years, Dr. Krumholz received expenses and/or personal fees from UnitedHealth, IBM Watson Health, Element Science, Aetna, Facebook, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, Martin/Baughman Law Firm, F-Prime, and the National Center for Cardiovascular Diseases in Beijing. He is an owner of Refactor Health and HugoHealth and had grants and/or contracts from the Centers for Medicare & Medicaid Services, Medtronic, the U.S. Food and Drug Administration, Johnson & Johnson, and the Shenzhen Center for Health Information. Dr. Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the Yale Center for Implementation Science. She was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion. Dr. Melnick is supported in part by the National Institute On Drug Abuse of the National Institutes of Health under Award Number UH3DA047003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a review article that is exempted from IRB review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are included in the online supplemental material.